Market Research Industry Reports

Ligand Pharmaceuticals Inc (LGND) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company employs research technologies including nuclear receptor assays, formulation science, high throughput computer screening, antibody discovery technologies and liver targeted pro-drug technologies to assist companies in securing prescription drug approvals. It provides a diversified portfolio of biotechnology and pharmaceutical products for fungal infections, hepatitis C, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand also offers late-stage development, regulatory management and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc (LGND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 6
List of Figures 7
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis 20
Venture Financing 21
Nucorion Pharma Raises USD5 Million in Series A Venture Financing 21
Partnerships 22
Ligand Pharma Enters into Agreement with venBio 22
Ligand Pharma Enters into Agreement with AiCuris 23
Symphogen Enters Into Agreement With Open Monoclonal Technology 24
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 26
Open Monoclonal Expands Agreement with CNA Development 27
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 28
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 29
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 30
WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 31
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 32
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 33
Licensing Agreements 34
WuXi Biologics Ireland Enters into Licensing Agreement with Ligand Pharma 34
Roivant Sciences Enters into Licensing Agreement with Ligand Pharma 35
Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 36
Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 37
Amgen Enters into Licensing Agreement with Ligand Pharma 38
Surface Oncology Enters into Licensing Agreement with Ligand Pharma 39
xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 40
Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 41
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 42
CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 43
Novartis Enters into Licensing Agreement with Ligand Pharma 44
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 45
Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 46
Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 47
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 48
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 49
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 50
RODES Enters into Licensing Agreement with Ligand Pharma 51
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 52
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 53
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 54
Sanofi Enters into Licensing Agreement with Ligand Pharma 55
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 56
Open Monoclonal Enters into Licensing Agreement with Celgene 57
Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 58
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 59
Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 60
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 62
Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 63
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 64
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 65
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 66
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 67
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 69
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 70
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 71
Ligand Pharma Amends Licensing Agreement with Retrophin 72
TeneoBio Enters into Licensing Agreement with Ligand Pharma 74
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 75
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 76
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 77
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 78
Open Monoclonal Enters into Licensing Agreement with Amgen 79
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 80
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 81
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 82
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 83
Ligand Pharma Enters Into Licencing Agreement With Merck 84
Equity Offering 85
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 85
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 86
Debt Offering 87
Ligand Pharma Raises USD750 Million in Private Placement of Notes Due 2023 87
Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 88
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 90
Acquisition 91
Ligand Pharma to Acquire Crystal Bioscience 91
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 92
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technologys Spin-Out Companies 93
Ligand Pharmaceuticals Inc - Key Competitors 94
Ligand Pharmaceuticals Inc - Key Employees 95
Ligand Pharmaceuticals Inc - Locations And Subsidiaries 96
Head Office 96
Other Locations & Subsidiaries 96
Recent Developments 98
Financial Announcements 98
May 08, 2018: Ligand Reports First Quarter 2018 Financial Results May 8, 2018 98
Feb 21, 2018: Ligand Reports Fourth Quarter and Full Year 2017 Financial Results 101
Nov 09, 2017: Ligand Reports Third Quarter 2017 Financial Results 104
Aug 07, 2017: Ligand Reports Second Quarter 2017 Financial Results 107
May 09, 2017: Ligand Reports First Quarter 2017 Financial Results 110
Feb 23, 2017: Ligand Reports Fourth Quarter and Full Year 2016 Financial Results 113
Corporate Communications 116
Aug 21, 2017: Ligand Appoints Dr. Nancy Gray to its Board of Directors 116
Other Significant Developments 117
Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb platform to develop fully human antibodies 117
Feb 28, 2017: Ligand Provides Highlights From Analyst Day Event 118
Appendix 120
Methodology 120
About GlobalData 120
Contact Us 120
Disclaimer 120

List Of Tables

List of Tables
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ligand Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis 20
Nucorion Pharma Raises USD5 Million in Series A Venture Financing 21
Ligand Pharma Enters into Agreement with venBio 22
Ligand Pharma Enters into Agreement with AiCuris 23
Symphogen Enters Into Agreement With Open Monoclonal Technology 24
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 26
Open Monoclonal Expands Agreement with CNA Development 27
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 28
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 29
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 30
WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 31
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 32
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 33
WuXi Biologics Ireland Enters into Licensing Agreement with Ligand Pharma 34
Roivant Sciences Enters into Licensing Agreement with Ligand Pharma 35
Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 36
Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 37
Amgen Enters into Licensing Agreement with Ligand Pharma 38
Surface Oncology Enters into Licensing Agreement with Ligand Pharma 39
xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 40
Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 41
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 42
CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 43
Novartis Enters into Licensing Agreement with Ligand Pharma 44
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 45
Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 46
Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 47
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 48
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 49
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 50
RODES Enters into Licensing Agreement with Ligand Pharma 51
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 52
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 53
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 54
Sanofi Enters into Licensing Agreement with Ligand Pharma 55
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 56
Open Monoclonal Enters into Licensing Agreement with Celgene 57
Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 58
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 59
Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 60
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 62
Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 63
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 64
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 65
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 66
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 67
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 69
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 70
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 71
Ligand Pharma Amends Licensing Agreement with Retrophin 72
TeneoBio Enters into Licensing Agreement with Ligand Pharma 74
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 75
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 76
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 77
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 78
Open Monoclonal Enters into Licensing Agreement with Amgen 79
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 80
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 81
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 82
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 83
Ligand Pharma Enters Into Licencing Agreement With Merck 84
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 85
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 86
Ligand Pharma Raises USD750 Million in Private Placement of Notes Due 2023 87
Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 88
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 90
Ligand Pharma to Acquire Crystal Bioscience 91
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 92
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technologys Spin-Out Companies 93
Ligand Pharmaceuticals Inc, Key Competitors 94
Ligand Pharmaceuticals Inc, Key Employees 95
Ligand Pharmaceuticals Inc, Subsidiaries 96

List Of Figures

List of Figures
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13

Ligand Pharmaceuticals Inc (LGND) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company employs research technologies including nuclear receptor assays, formulation science, high throughput computer

USD 250View Report

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Pipeline Review, H1 2018

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Pipeline

USD 3500View Report

Alexza Pharmaceuticals Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Alexza Pharmaceuticals Inc (Alexza), a wholly owned subsidiary of Ferrer Therapeutics Inc, focuses on the research, development and commercialization of novel, proprietary products for the treatment of acute central nervous

USD 250View Report

Ra Pharmaceuticals Inc (RARX) - Medical Equipment - Deals and Alliances Profile

Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :120
Country :United States of America
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube